Story

Indra Shares Jump After Morgan Stanley Upgrade on Defense Spending Outlook

ENTHMSVIIDZHZH-TWJAKOHI
Jul 14, 20261 min read
Indra Shares Jump After Morgan Stanley Upgrade on Defense Spending Outlook

Summary

Shares in the Spanish technology and defense firm surged after Morgan Stanley upgraded the stock to 'Overweight' and raised its price target, citing underestimated benefits from Spain's rising military budget.

Text size
Background

Shares in Spanish defense and technology company Indra (LON:0HA9) rose more than 3% on Tuesday after Morgan Stanley upgraded its rating on the stock to Overweight from Equal-weight. The investment bank cited an underappreciated earnings potential driven by Spain's expanding defense budget.

Following the announcement, Indra's stock gained 3.2% to trade at €48.38, outperforming the broader European market.

Analyst's Bullish Thesis

Morgan Stanley raised its price target for Indra to €70 from €60, which implies a potential upside of approximately 50% from the stock's closing price on Monday. The bank's positive outlook is rooted in the expectation that Indra will be a primary beneficiary of a multi-year increase in Spanish military procurement.

According to the brokerage's note, Spain's spending on defense equipment is projected to nearly double by 2030 as the government proceeds with a major modernization program. This trend is expected to position Indra's defense business as the group's largest revenue generator by the end of the decade.

Financial Projections and Catalysts

Sample IUX Markets – In-articleAd

Morgan Stanley's analysts forecast that Indra's earnings in 2030 could be about 13% above current Wall Street consensus expectations. The bank also suggested that Indra could achieve its strategic goals of approximately €10 billion in revenue and a 12% EBIT margin as early as 2029, a year ahead of the company's own guidance.

Potential future catalysts for the stock identified by the bank include:

  • The company's upcoming second-quarter earnings report on July 23.
  • A capital markets day scheduled for later this year.
  • Continued execution of Spain's national defense modernization plans.

The note also mentioned that additional acquisitions could provide further upside to the company's growth trajectory.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST